Skip to main content

Ultivue, OracleBio Collaborate on Tissue Biomarker Analysis Workflow

NEW YORK -- Ultivue said Wednesday that it has entered a collaborative partnership with OracleBio to combine their respective technologies for tissue staining and histopathology image analysis to provide pharmaceutical companies with an end-to-end workflow for tissue-based biomarker analysis. 

The firm said the partnership aims to advance personalized tumor characterization in oncology research and drug development via multiplex immunofluorescence staining and imaging. 

OracleBio, a contract research organization based in Scotland, provides quantitative digital pathology services in support of both clinical and pre-clinical research. 

Cambridge, Massachusetts-based Ultivue develops tissue staining reagents for multiplex immunofluorescence imaging and analysis. ItInSituPlex technology uses proprietary antibody-DNA barcoding and signal amplification to enable multiplexed biomarker detection and analysis that is compatible with a range of histopathology instrumentation and imaging tools. 

Quantitative histopathology analysis can be heavily dependent on the quality of sample preparation and staining," Lorcan Sherry, CSO of OracleBio, said in a statement. "Being able to partner with Ultivue means we can be confident in the staining of the tissue we’re quantifying, which ultimately means more precise data," he added. 

Financial terms were not disclosed.